Print Clear

Prior Authorization Request Administrative Information

Member information

Last name _____ First name _____ MI _____

Member ID _____ Date of birth _____

Sex assigned at birth ☐ Female ☐ Male ☐ "X" or Intersex

Current gender ☐ Female ☐ Male ☐ Transgender male ☐ Transgender female ☐ Other _____

Place of residence ☐ Home ☐ Nursing facility ☐ Other _____

Race _____ Ethnicity _____

Preferred spoken language _____ Preferred written language _____

MassHealth does not exclude people or treat them differently because of race, color, national origin, age, disability, religion, creed, sexual orientation, or sex (including gender identity and gender stereotyping).

Plan contact information

Please indicate the member's MassHealth Plan and fax or submit this completed and signed form according to the Plan's contact information below.

MassHealth Fee-For-Service (FFS) Plan, Primary Care Clinician (PCC) Plan, Primary Care Accountable Care Organization (PCACO) Plan, Children's Medical Security Plan, and Health Safety Net Plan
☐ **MassHealth Drug Utilization Review Program** Pharmacy: Fax: (877) 208-7428 - Tel: (800) 745-7318
MassHealth Managed Care Organization (MCO) and Accountable Care Partnership Plans (ACPP)
☐ **Fallon Health** Online Prior Authorization: go.covermymeds.com/OptumRx Online Prior Authorization: providerportal.surescripts.net/ProviderPortal/optum Pharmacy: Fax: (844) 403-1029 - Tel: (844) 720-0033
☐ **Health New England** Online Prior Authorization: go.covermymeds.com/OptumRx Pharmacy: Fax: (800) 550-9246 - Tel: (800) 918-7545
☐ **Mass General Brigham Health Plan** Online Prior Authorization (Non-Specialty Drugs): go.covermymeds.com/OptumRx Online Prior Authorization (Specialty/Medical Drugs): provider.massgeneralbrighamhealthplan.org Pharmacy: Fax: (844) 403-1029 - Tel: (800) 711-4555
☐ **Tufts Health Plan** Online Prior Authorization: point32health.promptpa.com Pharmacy: Fax: (617) 673-0939 - Tel: (888) 257-1985
☐ **WellSense Health Plan** Online Prior Authorization: wellsense.org/providers/ma/pharmacy/prior-authorizations Pharmacy: Fax: (833) 951-1680 - Tel: (877) 417-1822

over

Opioid Dependence and Reversal Agents
Prior Authorization Request

MassHealth reviews requests for prior authorization (PA) on the basis of medical necessity only. If MassHealth approves the request, payment is still subject to all general conditions of MassHealth, including current member eligibility, other insurance, and program restrictions. MassHealth will notify the requesting provider and member of its decision. Keep a copy of this form for your records. If faxing this form, please use black ink.

Additional information about these agents, including PA requirements and preferred products, can be found within the MassHealth Drug List at **www.mass.gov/druglist.**

Medication information

Medication requested

☐ Brixadi (buprenorphine extended-release injection)

☐ buprenorphine sublingual tablet ☐ 2 mg ☐ 8 mg

☐ buprenorphine/naloxone film ☐ 2 mg/0.5 mg ☐ 4 mg/1 mg ☐ 8 mg/2 mg ☐ 12 mg/3 mg

☐ buprenorphine/naloxone sublingual tablet ☐ 2 mg/0.5 mg ☐ 8 mg/2 mg

☐ Lifems (naloxone syringe kit)

☐ lofexidine

☐ Opvee (nalmefene nasal spray)

☐ Zubsolv (buprenorphine/naloxone sublingual tablet) ☐ 0.7 mg/0.18 mg ☐ 1.4 mg/0.36 mg ☐ 2.9 mg/0.71 mg ☐ 5.7 mg/1.4 mg ☐ 8.6 mg/2.1 mg ☐ 11.4 mg/2.9 mg

Dose, frequency, and duration of medication requested

For all requests for medications containing buprenorphine, is the member maintained on the lowest effective dose?

☐ Yes ☐ No. If no, please provide complete treatment plan.

Indication (Check all that apply or include ICD-10 code, if applicable.)

☐ Management of opioid withdrawal symptoms ☐ Opioid overdose prevention/reversal

☐ Opioid dependence ☐ Other

Section I. Please complete for all requests.

1. Please indicate billing preference. ☐ Pharmacy ☐ Prescriber in-office ☐ Hospital outpatient
   If applicable, please also complete section for professionally administered medications at end of form.
2. Drug NDC (if known) or service code
3. Has the prescriber evaluated the Massachusetts Prescription Awareness Tool (MassPAT) data? ☐ Yes ☐ No
4. Is this member a referral candidate for care coordination? ☐ Yes ☐ No

If yes, MassHealth will offer this member care coordination services. Please describe which additional behavioral health services would be beneficial. *Please inform the member, parent, or legal guardian to expect outreach from a MassHealth representative of care coordination services.*

Section II. Please complete for buprenorphine tablet requests.

1. Is the member pregnant? ☐ Yes. Anticipated date of delivery ☐ No
2. Is the member breastfeeding? ☐ Yes ☐ No

3. Does the member have a documented allergy to naloxone? ☐ Yes ☐ No
   If yes, please provide medical records documenting the allergic reaction.
4. If you answered "No" to the three questions above, please provide medical necessity for prescribing buprenorphine rather than buprenorphine/naloxone. (Please explain below and provide medical records.)

Section III. Please complete for buprenorphine, buprenorphine/naloxone film, and buprenorphine/naloxone tablet doses exceeding 24 mg/day, and Zubsolv doses exceeding 17.2 mg/day.

Please document medical necessity for high dose of buprenorphine/naloxone and buprenorphine below and submit medical records supporting the medical necessity provided.

Section IV. Please complete for Zubsolv requests.

Has the member had an allergic reaction to buprenorphine/naloxone film?

☐ Yes. (Specify and provide medical records.)

☐ No. Please explain.

Section V. Please complete for lofexidine requests.

Has the member had a trial with oral clonidine?

☐ Yes. Please list the dose and frequency, dates/durations of use, and outcomes below.

Dose and frequency Dates/duration of use

Did the member experience any of the following? ☐ Adverse reaction ☐ Inadequate response ☐ Other

Briefly describe details of adverse reaction, inadequate response, or other.

☐ No. Please describe clinical rationale why the member is not a candidate for oral clonidine.

Section VI. Please complete for Lifems requests.

Please document medical necessity for the convenience kit formulation, as it pertains to the caregiver.

Section VII. Please complete for Brixadi requests.

1. Has the member been initiated on treatment with a single dose of a transmucosal buprenorphine product or is already being treated with buprenorphine? ☐ Yes ☐ No
2. Has the member had a trial with Sublocade?
   ☐ Yes. Please describe the outcome. ☐ Adverse reaction ☐ Inadequate response ☐ Other
   Briefly describe the details of adverse reaction, inadequate response, or other.

over

☐ No. Please provide clinical rationale for use of the requested agent instead of Sublocade.

Section VIII. Please complete for Opvee requests.

Please provide medical necessity for use of a long-acting formulation for overdose reversal.

Section IX. Please complete and provide documentation for exceptions to step therapy.

1. Is the alternative drug required under the step therapy protocol contraindicated, or will likely cause an adverse reaction in, or physical or mental harm to, the member? ☐ Yes ☐ No
   If yes, briefly describe details of contraindication, adverse reaction, or harm.
2. Is the alternative drug required under the step therapy protocol expected to be ineffective based on the known clinical characteristics of the member and the known characteristics of the alternative drug regimen? ☐ Yes ☐ No
   If yes, briefly describe details of known clinical characteristics of member and alternative drug regimen.
3. Has the member previously tried the alternative drug required under the step therapy protocol, or another alternative drug in the same pharmacologic class or with the same mechanism of action, and such alternative drug was discontinued due to lack of efficacy or effectiveness, diminished effect, or an adverse event? ☐ Yes ☐ No
   If yes, please provide details for the previous trial.
   Drug name Dates/duration of use
   Did the member experience any of the following? ☐ Adverse reaction ☐ Inadequate response
   Briefly describe details of adverse reaction or inadequate response.
4. Is the member stable on the requested prescription drug prescribed by the health care provider, and switching drugs will likely cause an adverse reaction in, or physical or mental harm to, the member?
   ☐ Yes. Please provide details.
   ☐ No

Please continue to next page and complete Prescriber and Provider Information section.

over

Prior Authorization Request Prescriber and Provider Information

Prescriber information

Last name* First name* MI

NPI* Individual MH Provider ID

DEA No. Office Contact Name

Address City State Zip

E-mail address

Telephone No.*

Fax No.* (Please provide fax number for PA response notification.)

** Required*

Please also complete for professionally administered medications, if applicable.

Start date End date

Servicing prescriber/facility name ☐ Same as prescribing provider

Servicing provider/facility address

Servicing provider NPI/tax ID No.

Name of billing provider

Billing provider NPI No.

Is this a request for recertification? ☐ Yes ☐ No

CPT code No. of visits J code No. of units

Provider's attestation, signature, and date

I certify under the pains and penalties of perjury that I am either the prescribing provider or duly authorized to act on behalf of the provider identified in the Prescriber information section of this form. Any attached statement on letterhead has been reviewed and signed by me. I certify that the medical necessity information (per 130 CMR 450.204) on this form is true, accurate, and complete, to the best of my knowledge. I understand that I may be subject to civil penalties or criminal prosecution for any falsification, omission, or concealment of any material fact contained herein.

Signature of provider or individual duly authorized to act on behalf of the provider:

Printed legal name and title of signatory above

Date

(The form can either be signed by hand and then scanned, or it can be signed electronically using DocuSign or Adobe Sign. For electronic signatures, the signer can upload a picture of their wet signature. The typed text of a signature is not an acceptable form of an electronic signature.)